Rhenman & Partners Asset Management Ab Has Trimmed Aerie Pharmaceuticals (AERI) Position as Share Value Declined; As Cognizant Technology Solutio (CTSH) Market Valuation Rose, Meru Capital Group LP Boosted Stake

November 15, 2017 - By Hazel Jackson

Rhenman & Partners Asset Management Ab decreased its stake in Aerie Pharmaceuticals Inc (AERI) by 11.76% based on its latest 2017Q2 regulatory filing with the SEC. Rhenman & Partners Asset Management Ab sold 10,000 shares as the company’s stock declined 8.47% while stock markets rallied. The institutional investor held 75,000 shares of the health care company at the end of 2017Q2, valued at $3.94M, down from 85,000 at the end of the previous reported quarter. Rhenman & Partners Asset Management Ab who had been investing in Aerie Pharmaceuticals Inc for a number of months, seems to be less bullish one the $2.22B market cap company. The stock decreased 2.88% or $1.8 during the last trading session, reaching $60.6. About shares traded. Aerie Pharmaceuticals Inc (NASDAQ:AERI) has risen 180.20% since November 15, 2016 and is uptrending. It has outperformed by 163.50% the S&P500.

Guru Ramakrishnan increased its stake in Cognizant Technology Solutio (CTSH) by 53.3% based on its latest 2017Q2 regulatory filing with the SEC. Meru Capital Group Lp bought 22,600 shares as the company’s stock rose 12.87% with the market. The hedge fund run by Guru Ramakrishnan held 65,000 shares of the edp services company at the end of 2017Q2, valued at $4.32M, up from 42,400 at the end of the previous reported quarter. Meru Capital Group Lp who had been investing in Cognizant Technology Solutio for a number of months, seems to be bullish on the $44.21 billion market cap company. The stock increased 0.55% or $0.41 during the last trading session, reaching $74.97. About 50 shares traded. Cognizant Technology Solutions Corp (NASDAQ:CTSH) has risen 5.50% since November 15, 2016 and is uptrending. It has underperformed by 11.20% the S&P500.




More notable recent Cognizant Technology Solutions Corp (NASDAQ:CTSH) news were published by: Fool.com which released: “Digital Shift Keeps Pushing Cognizant Technology’s Business Forward” on November 01, 2017, also Nasdaq.com with their article: “Seizert Capital Partners, Llc Buys The Middleby Corp, Cognizant Technology …” published on October 31, 2017, Gurufocus.com published: “Whitnell & Co. Buys DowDuPont Inc, Cognizant Technology Solutions Corp, Sun …” on October 31, 2017. More interesting news about Cognizant Technology Solutions Corp (NASDAQ:CTSH) were released by: Nasdaq.com and their article: “Whitnell & Co. Buys DowDuPont Inc, Cognizant Technology Solutions Corp, Sun …” published on November 01, 2017 as well as Reuters.com‘s news article titled: “Cognizant’s financial revenue growth slows, shares fall” with publication date: November 01, 2017.

Among 30 analysts covering Cognizant Technology Solutions Corp. (NASDAQ:CTSH), 23 have Buy rating, 1 Sell and 6 Hold. Therefore 77% are positive. Cognizant Technology Solutions Corp. had 73 analyst reports since August 6, 2015 according to SRatingsIntel. The firm has “Strong Buy” rating by Needham given on Wednesday, November 1. The firm earned “Buy” rating on Friday, September 30 by HSBC. On Thursday, October 12 the stock rating was maintained by Robert W. Baird with “Buy”. Wedbush initiated it with “Neutral” rating and $65 target in Friday, September 9 report. The firm earned “Buy” rating on Thursday, August 3 by RBC Capital Markets. The firm has “Buy” rating by Citigroup given on Wednesday, July 20. The rating was downgraded by Morgan Stanley on Tuesday, January 31 to “Equal-Weight”. Cowen & Co maintained Cognizant Technology Solutions Corp (NASDAQ:CTSH) on Friday, July 28 with “Buy” rating. On Tuesday, August 11 the stock rating was maintained by Argus Research with “Buy”. The firm has “Buy” rating given on Tuesday, November 8 by Needham.

Since May 16, 2017, it had 0 insider purchases, and 8 insider sales for $2.26 million activity. Another trade for 4,000 shares valued at $271,000 was made by KRISHNASWAMY VENKAT on Monday, June 5. On Thursday, May 25 CHATTERJEE DEBASHIS sold $46,230 worth of Cognizant Technology Solutions Corp (NASDAQ:CTSH) or 690 shares. Another trade for 10,000 shares valued at $674,365 was made by Kandiah Gajakarnan Vibushanan on Tuesday, June 6. $282,815 worth of Cognizant Technology Solutions Corp (NASDAQ:CTSH) was sold by Shaheen Allen. On Tuesday, May 16 SINHA DHARMENDRA KUMAR sold $601,445 worth of Cognizant Technology Solutions Corp (NASDAQ:CTSH) or 9,253 shares. Another trade for 3,069 shares valued at $199,485 was sold by Veeraraghavachary Srinivasan.

Investors sentiment decreased to 0.76 in 2017 Q2. Its down 0.15, from 0.91 in 2017Q1. It worsened, as 53 investors sold CTSH shares while 330 reduced holdings. 86 funds opened positions while 205 raised stakes. 503.05 million shares or 1.75% less from 512.00 million shares in 2017Q1 were reported. Fifth Third Bankshares reported 0.01% of its portfolio in Cognizant Technology Solutions Corp (NASDAQ:CTSH). Vision Mngmt holds 1.22% or 53,666 shares. Hilltop Incorporated holds 0.17% of its portfolio in Cognizant Technology Solutions Corp (NASDAQ:CTSH) for 8,589 shares. Moreover, Rmb Cap Mgmt Llc has 0.82% invested in Cognizant Technology Solutions Corp (NASDAQ:CTSH). Haverford Trust reported 0.01% stake. Prentiss Smith & holds 0.01% or 390 shares. 17 were accumulated by Howe & Rusling Inc. 9,471 are held by Private Trust Na. Horan Capital Advsrs Limited Liability Company invested in 21,545 shares or 0.97% of the stock. Northwestern Mutual Wealth Mngmt Company, Wisconsin-based fund reported 129,908 shares. Ballentine Prtn Ltd Limited Liability Company invested in 0.03% or 6,653 shares. Martin Currie reported 321,600 shares. Pekin Singer Strauss Asset Management Il invested 0.05% in Cognizant Technology Solutions Corp (NASDAQ:CTSH). Douglass Winthrop Advsr Limited Company reported 3,800 shares or 0.02% of all its holdings. Regentatlantic Capital Ltd Liability invested 0.07% in Cognizant Technology Solutions Corp (NASDAQ:CTSH).

Meru Capital Group Lp, which manages about $798.95M and $30.34 million US Long portfolio, decreased its stake in T Mobile Us Inc (NYSE:TMUS) by 141,200 shares to 100,000 shares, valued at $6.06M in 2017Q2, according to the filing. It also reduced its holding in Charter Communications Inc N by 40,260 shares in the quarter, leaving it with 10,000 shares, and cut its stake in Apple Inc (NASDAQ:AAPL).

Analysts await Aerie Pharmaceuticals Inc (NASDAQ:AERI) to report earnings on March, 6.

More notable recent Aerie Pharmaceuticals Inc (NASDAQ:AERI) news were published by: Seekingalpha.com which released: “This Might Be The Best Time To Pick Up Aerie Pharmaceuticals In 2017” on October 23, 2017, also Businesswire.com with their article: “Aerie Pharmaceuticals to Announce Third Quarter 2017 Financial Results and …” published on November 01, 2017, Businesswire.com published: “Aerie Pharmaceuticals Announces Appointment of John Maltman, Ph.D., as Vice …” on October 30, 2017. More interesting news about Aerie Pharmaceuticals Inc (NASDAQ:AERI) were released by: Digitaljournal.com and their article: “Aerie Pharmaceuticals, Inc. to Host Earnings Call” published on November 08, 2017 as well as Businesswire.com‘s news article titled: “Aerie Pharmaceuticals Reports Third Quarter 2017 Financial Results and …” with publication date: November 08, 2017.

Rhenman & Partners Asset Management Ab, which manages about $696.48M US Long portfolio, upped its stake in Neurocrine Biosciences Inc (NASDAQ:NBIX) by 35,000 shares to 120,000 shares, valued at $5.52 million in 2017Q2, according to the filing. It also increased its holding in Centene Corp (NYSE:CNC) by 12,407 shares in the quarter, for a total of 100,000 shares, and has risen its stake in Universal Health Services Inc B (NYSE:UHS).

Since May 26, 2017, it had 0 insider purchases, and 1 insider sale for $1.12 million activity.

Investors sentiment increased to 1.17 in Q2 2017. Its up 0.21, from 0.96 in 2017Q1. It is positive, as 21 investors sold AERI shares while 48 reduced holdings. 33 funds opened positions while 48 raised stakes. 31.61 million shares or 3.55% more from 30.53 million shares in 2017Q1 were reported. Financial Bank Of America De stated it has 34,134 shares or 0% of all its holdings. Essex Inv Management Ltd Liability Corporation has invested 0.58% in Aerie Pharmaceuticals Inc (NASDAQ:AERI). Alps Advsrs holds 0.01% in Aerie Pharmaceuticals Inc (NASDAQ:AERI) or 31,934 shares. The Quebec – Canada-based Sectoral Asset Incorporated has invested 2.31% in Aerie Pharmaceuticals Inc (NASDAQ:AERI). Proshare Advsrs Limited Liability accumulated 0.01% or 20,662 shares. Royal National Bank & Trust Of Canada reported 0% of its portfolio in Aerie Pharmaceuticals Inc (NASDAQ:AERI). Prudential stated it has 0.01% of its portfolio in Aerie Pharmaceuticals Inc (NASDAQ:AERI). Orbimed Limited Liability reported 1.83M shares. Consulate Inc stated it has 0.57% in Aerie Pharmaceuticals Inc (NASDAQ:AERI). Tudor Investment Et Al has invested 0.02% in Aerie Pharmaceuticals Inc (NASDAQ:AERI). Barclays Public Limited Liability Co owns 3,431 shares. Foresite Mngmt Ii Ltd Company has 40.27% invested in Aerie Pharmaceuticals Inc (NASDAQ:AERI) for 1.67 million shares. Boulegeris Invs owns 79,525 shares. Nicholas Prns Lp accumulated 71,800 shares. Alliancebernstein Limited Partnership accumulated 377,384 shares.

Among 14 analysts covering Aerie Pharmaceuticals (NASDAQ:AERI), 14 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aerie Pharmaceuticals had 41 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was initiated by H.C. Wainwright on Tuesday, September 20 with “Buy”. The firm earned “Buy” rating on Friday, September 22 by JMP Securities. The firm earned “Buy” rating on Tuesday, August 1 by Canaccord Genuity. Cantor Fitzgerald maintained the stock with “Buy” rating in Wednesday, October 11 report. The stock has “Buy” rating by Cowen & Co on Thursday, October 5. The stock of Aerie Pharmaceuticals Inc (NASDAQ:AERI) earned “Buy” rating by Stifel Nicolaus on Thursday, July 27. The company was maintained on Wednesday, September 20 by Canaccord Genuity. The firm has “Buy” rating by Aegis Capital given on Tuesday, November 1. The rating was reinitiated by Canaccord Genuity with “Buy” on Tuesday, December 20. The rating was maintained by Needham with “Buy” on Friday, September 15.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.